Reviewer's report

Title: A phase I study of daily treatment with a ceramide-dominant triple lipid mixture commencing in neonates

Version: 2 Date: 27 February 2012

Reviewer: Kyoung-Chan Park

Reviewer's report:

This is a paper which presented the result of phase 1 study of moisturizer. General outline of the paper looks fine but I am not sure whether it is suitable for publication.

1st comment

Phase 1 study is a clinical study to find out the chance of adverse effects of new drug. Because EpiCream® was approved by FDA, this is a well performed phase 1 study in neonates. As author claims, a number of adverse events occurred which are unlikely to be related to the study treatment. Because it is a phase 1 study, 10 normal infants with a family history of allergic disease were recruited. Then, conclusion is “FDA approved moisturizer did not show adverse event also in neonate”.

Editor's decision is necessary whether it is suitable for publication or not.

2nd comment

More detail information of moisturizer is necessary (especially what kind of ceramide is contained?)

Below are my opinions relating guideline

1. Is the question posed by the authors well defined? Yes
2. Are the methods appropriate and well described? Yes
3. Are the data sound? No
4. Does the manuscript adhere to the relevant standards for reporting and data deposition? Questionable
5. Are the discussion and conclusions well balanced and adequately supported by the data? Yes
6. Are limitations of the work clearly stated? No comments
7. Do the authors clearly acknowledge any work upon which they are building, both published and unpublished? Yes
8. Do the title and abstract accurately convey what has been found? Yes
9. Is the writing acceptable Yes